A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling
- 1Outpace Bio
Abstract
Cytokines mediate cell-cell communication to coordinate immune responses and hold clinical promise as immunotherapies. While natural cytokines are exquisitely regulated by immune cells, engineered cytokines have not yet matched this sophisticated regulation, limiting clinical efficacy and safety. IL-2 is an important cytokine involved in antitumor response, but its production is disrupted in the immune-suppressive tumor microenvironment. Here we designed a regulated IL-2 module, OUTSMART designed IL-2 (dIL-2), that functions robustly in solid tumors and reduces systemic activity that could trigger toxicity: we computationally redesigned IL-2 to have a novel topology that increases stability, preserves native IL-2R{beta}{gamma} interfaces, ablates IL-2R binding, and delivers IL-2 signaling to CD8+ immune-effector cells. This designed cytokine is genetically regulated by a T cell activation-responsive promoter, allowing dynamic production from chimeric antigen receptor (CAR) T cells. Like wild type IL-2, OUTSMART dIL-2 drives T cell proliferation and enhances effector function. Unlike wild type IL-2, it preferentially stimulates CD8+ T cells and Natural Killer (NK) cells, avoids T regulatory cells, and stimulates CAR-T proliferation while preserving stemness, achieving durable tumor elimination in two solid tumor animal models. These design principles can be applied to create other dynamically-regulated cytokine systems that address mechanisms of complex disease.
Related
- Symbiont spatial organisation is dynamically regulated within cnidarian host tissues
- Glutamine-regulated VCP acetylation creates a proteostasis vulnerability in RB1-deficient tumor
- Complement Signaling and Regulated Cell Death in Immune-Mediated Glomerular Injury.
- Tceal7 is a BRG1-regulated target of calcineurin signaling that promotes myoblast differentiation
- Provisional extracellular matrix signaling network regulates tumor lymphoneogenesis and response to immunotherapy
BibTeX
@misc{moffett2026dynamically,
title = {{A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling}},
author = {H. F. Moffett and B. D. Weitzner and M. M. Lissner and T. M. Davenport and K. G. Haworth and E. T. Hayes and R. A. Langan and L. J. Tait and W. M. Obenza and B. Hammerson and L. E. Baker and J. T. Crowl and J. L. Hammer and T. Tan and V. R. Montoya and J. C. Chen and D. S. Clausen and P. J. Sample and A. H. Ng and S. Yuan and R. H. Amin and A. E. Foster and S. E. Boyken and M. J. Lajoie},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.18.752703},
url = {https://www.biorxiv.org/content/10.64898/2026.09.18.752703v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling
AU - H. F. Moffett
AU - B. D. Weitzner
AU - M. M. Lissner
AU - T. M. Davenport
AU - K. G. Haworth
AU - E. T. Hayes
AU - R. A. Langan
AU - L. J. Tait
AU - W. M. Obenza
AU - B. Hammerson
AU - L. E. Baker
AU - J. T. Crowl
AU - J. L. Hammer
AU - T. Tan
AU - V. R. Montoya
AU - J. C. Chen
AU - D. S. Clausen
AU - P. J. Sample
AU - A. H. Ng
AU - S. Yuan
AU - R. H. Amin
AU - A. E. Foster
AU - S. E. Boyken
AU - M. J. Lajoie
PY - 2026
DA - 2026/09/18
PB - bioRxiv
DO - 10.64898/2026.09.18.752703
UR - https://www.biorxiv.org/content/10.64898/2026.09.18.752703v1
AB - Cytokines mediate cell-cell communication to coordinate immune responses and hold clinical promise as immunotherapies. While natural cytokines are exquisitely regulated by immune cells, engineered cytokines have not yet matched this sophisticated regulation, limiting clinical efficacy and safety. IL-2 is an important cytokine involved in antitumor response, but its production is disrupted in the immune-suppressive tumor microenvironment. Here we designed a regulated IL-2 module, OUTSMART designed IL-2 (dIL-2), that functions robustly in solid tumors and reduces systemic activity that could trigger toxicity: we computationally redesigned IL-2 to have a novel topology that increases stability, preserves native IL-2R{beta}{gamma} interfaces, ablates IL-2R binding, and delivers IL-2 signaling to CD8+ immune-effector cells. This designed cytokine is genetically regulated by a T cell activation-responsive promoter, allowing dynamic production from chimeric antigen receptor (CAR) T cells. Like wild type IL-2, OUTSMART dIL-2 drives T cell proliferation and enhances effector function. Unlike wild type IL-2, it preferentially stimulates CD8+ T cells and Natural Killer (NK) cells, avoids T regulatory cells, and stimulates CAR-T proliferation while preserving stemness, achieving durable tumor elimination in two solid tumor animal models. These design principles can be applied to create other dynamically-regulated cytokine systems that address mechanisms of complex disease.
ER -